JPM vs MGLD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
The Marygold Companies exhibits severe financial weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating a significant deterioration in fundamental health. While the company maintains a strong liquidity position with a current ratio of 3.90 and very low debt, it is plagued by negative profit margins (-11.85%) and shrinking year-over-year revenue growth (-4.50%). The combination of negative ROE, a bearish technical trend, and a high Price-to-Book ratio (2.08) for a loss-making entity suggests the stock is fundamentally overvalued. Despite a slight recovery in 1-year price performance, the long-term 5-year trend remains deeply negative (-67.5%).
Compare Another Pair
Related Comparisons
JPM vs MGLD: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and The Marygold Companies, Inc. (MGLD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.